Genetic Testing for Breast and Ovarian Cancer

Plan: AmeriHealth Caritas Louisiana

Clinical Policy ID: CCP.4012

Recent review date: 2/2025

Next review date: 6/2026

Policy contains: Breast cancer; Ovarian cancer; Genetic testing; BRCA1; BRCA2; cancer-affected; cancer-unaffected; LDH Provider Policy.

AmeriHealth Caritas Louisiana has developed clinical policies to assist with making coverage determinations. AmeriHealth Caritas Louisiana's clinical policies are based on guidelines from established industry sources, such as the Centers for Medicare & Medicaid Services (CMS), state regulatory agencies, the American Medical Association (AMA), medical specialty professional societies, and peer-reviewed professional literature. These clinical policies along with other sources, such as plan benefits and state and federal laws and regulatory requirements, including any state- or plan-specific definition of "medically necessary," and the specific facts of the particular situation are considered, on a case-by-case basis by AmeriHealth Caritas Louisiana when making coverage determinations. In the event of conflict between this clinical policy and plan benefits and/or state or federal laws and/or regulatory requirements, the plan benefits and/or state and federal laws and/or regulatory requirements shall control. AmeriHealth Caritas Louisiana's clinical policies are for informational purposes only and not intended as medical advice or to direct treatment. Physicians and other health care providers are solely responsible for the treatment decisions for their patients. AmeriHealth Caritas Louisiana's clinical policies are reflective of evidence-based medicine at the time of review. As medical science evolves, AmeriHealth Caritas Louisiana will update its clinical policies as necessary. AmeriHealth Caritas Louisiana's clinical policies are not guarantees of payment.

Policy statement

Genetic testing is clinically proven and, therefore, may be medically necessary for BRCA1 and BRCA2 mutations in cancer-affected and cancer-unaffected members when the following criteria are met:

Members meeting one or more of the below criteria are considered eligible.

- Members with any blood relative with a known BRCA1/BRCA2 mutation;
- Members meeting the criteria below but with previous limited testing (e.g., single gene and/or absent deletion duplication analysis) interested in pursuing multi-gene testing;
- Members with a personal history of cancer, defined as one or more of the following:
    - Breast cancer and one or more of the following:
        - Diagnosed age ≤ 45 years; or
        - Diagnosed at age 45—50 years with:
            - Unknown or limited family history; or
            - A second breast cancer diagnosed at any age; or
            - ≥ 1 close blood relative* with breast, ovarian, pancreatic, or high-grade (Gleason score ≥ 7) or intraductal prostate cancer at any age
        - Diagnosed at age ≤ 60 years with triple negative (ER–, PR–, HER2–) breast cancer;
        - Diagnosed at any age with:
            - Ashkenazi Jewish ancestry; or

- ≥ 1 close blood relative* with breast cancer at age ≤50 years or ovarian, pancreatic, or metastatic or intraductal prostate cancer at any age; or
- ≥ 3 total diagnoses of breast cancer in patient and/or close blood relatives*
  - Diagnosed at any age with male breast cancer; or
  - Epithelial ovarian cancer (including fallopian tube cancer or peritoneal cancer) at any age;
- Exocrine pancreatic cancer at any age;
- Metastatic or intraductal prostate cancer at any age;
- High-grade (Gleason score ≥ 7) prostate cancer at any age with:
  - Ashkenazi Jewish ancestry; or
  - ≥ 1 close blood relative* with breast cancer at age ≤ 50 years or ovarian, pancreatic, or metastatic or intraductal prostate cancer at any age; or
  - ≥ 2 close blood relatives* with breast or prostate cancer (any grade) at any age
- A mutation identified on tumor genomic testing that has clinical implications if also identified in the germline;
- To aid in systemic therapy decision-making, such as for HER2-negative metastatic breast cancer.

- Members with a family history of cancer, including unaffected members, defined as one or more of the following:
  - An affected or unaffected member with a 1st- or 2nd-degree blood relative meeting any of the criterion listed above (except members who meet criteria only for systemic therapy decision-making); or
  - An affected or unaffected member who otherwise does not met criteria above but also has a probability > 5% of a BRCA1/2 pathogenic variant based on prior probability models (e.g., Tyer-Cuzick, BRCAPro, PennII)

*For the purpose of familial assessment, close blood relatives include first-, second-, and third-degree relatives on the same side of the family (maternal or paternal):

- 1st-degree relatives are parents, siblings, and children;
- 2nd-degree relatives are grandparents, aunts, uncles, nieces, nephews, grandchildren, and half siblings; or
- 3rd-degree relatives are great-grandparents, great-aunts, great-uncles, great-grandchildren and first cousins.

Limitations:

None.

Exemptions:

None.

References

Louisiana Department of Health. 2012. *Medicaid Professional Services Provider Manual.* Genetic Testing for Breast and Ovarian Cancer, Chapter Five, Section 5.1. Issued 08/04/2025.

Policy updates

Initial review date: 3/2/2021

2/2023: Policy references updated.

2/2024: Policy references updated.

2/2025: Policy references updated.

2/2026: Policy references updated.

Related Codes

Below are the most commonly submitted codes for the service(s)/item(s) subject to this policy CCP.4012. This is not an exhaustive list of codes. Providers are expected to consult the appropriate coding manuals and bill accordingly.

Code	Code Description
81162	BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis and full duplication/deletion analysis (ie, detection of large gene rearrangements)
81163	BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis
81164	BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)
81165	BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis
81166	BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)
81167	BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)
81212	BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; 185delAG, 5385insC, 6174delT variants
81215	BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant
81216	BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis
81217	BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant
81432	Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer); genomic sequence analysis panel, must include sequencing of at least 10 genes, always including BRCA1, BRCA2, CDH1, MLH1,
81433	Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer); duplication/deletion analysis panel, must include analyses for BRCA1, BRCA2, MLH1, MSH2, and STK11